Abstract
Background
Kaposi sarcoma (KS) is one of common HIV-associated cancer. The availability of antiretroviral therapy (ART), liposomal doxorubicin, and several chemotherapy drugs have been reported the efficacy and tolerable side effect in case series and retrospective study. However, little is known the best chemotherapy regimen in this population. Thus, this systematic review intends to evaluate the best availability chemotherapy regimens for KS in HIV/AIDS patients.
Method
We conducted a systematic search through electronic databases that include Pubmed, PMC, Embase, Scopus, ScienceDirect until September 14th, 2022, using terms related to “chemotherapy regimen” AND “Kaposi sarcoma” AND “HIV/AIDS patient”. The search is limited to studies published in the last 20 years and randomized controlled trials (RCT). All studies were assessed using the JADAD scale for study quality.
Results
A total of 10 RCT studies consisting of 1528 Kaposi sarcoma patients were included in this study, with 63% of the patients were male. All 10 studies stated that the combined therapy of chemotherapy (paclitaxel or vincristine) plus other treatment modalities, such as highly activated antiretroviral therapy (HAART) and pegylated liposomal doxorubicin, is superior in overall response rate, quality of life, and overall survival compared to monotherapy regimen. As for adverse effects, the most common were grade 1 and 2 anaemia, neutropenia, and polyneuropathy. Assessment using the JADAD scale shows 7 studies in high quality and 3 studies in moderate quality.
Conclusion
Recent RCTs have shown efficacy and safety of combination of several chemotherapy regimens with other treatment modalities for KS in HIV/AIDS patients. Further studies to find the better regimens to improve overall survival of KS in this population.
Kaposi sarcoma (KS) is one of common HIV-associated cancer. The availability of antiretroviral therapy (ART), liposomal doxorubicin, and several chemotherapy drugs have been reported the efficacy and tolerable side effect in case series and retrospective study. However, little is known the best chemotherapy regimen in this population. Thus, this systematic review intends to evaluate the best availability chemotherapy regimens for KS in HIV/AIDS patients.
Method
We conducted a systematic search through electronic databases that include Pubmed, PMC, Embase, Scopus, ScienceDirect until September 14th, 2022, using terms related to “chemotherapy regimen” AND “Kaposi sarcoma” AND “HIV/AIDS patient”. The search is limited to studies published in the last 20 years and randomized controlled trials (RCT). All studies were assessed using the JADAD scale for study quality.
Results
A total of 10 RCT studies consisting of 1528 Kaposi sarcoma patients were included in this study, with 63% of the patients were male. All 10 studies stated that the combined therapy of chemotherapy (paclitaxel or vincristine) plus other treatment modalities, such as highly activated antiretroviral therapy (HAART) and pegylated liposomal doxorubicin, is superior in overall response rate, quality of life, and overall survival compared to monotherapy regimen. As for adverse effects, the most common were grade 1 and 2 anaemia, neutropenia, and polyneuropathy. Assessment using the JADAD scale shows 7 studies in high quality and 3 studies in moderate quality.
Conclusion
Recent RCTs have shown efficacy and safety of combination of several chemotherapy regimens with other treatment modalities for KS in HIV/AIDS patients. Further studies to find the better regimens to improve overall survival of KS in this population.
| Original language | English |
|---|---|
| Pages (from-to) | S1410 |
| Journal | Annals of Oncology |
| Volume | 34 |
| DOIs | |
| Publication status | Published - 1 Nov 2023 |
